anidulafungin has been researched along with Neutropenia in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andes, D; Ashbeck, J; Diekema, DJ; Hou, J; Marchillo, K; Pfaller, MA; Prince, RA | 1 |
| Chittick, P; Delashmitt, B; Evans, J; Palavecino, EL; Peacock, JE | 1 |
| Bakker-Woudenberg, IA; Mathot, RA; Rijnders, BJ; Tavakol, M; ten Kate, MT; van de Sande, WW; van Vianen, W | 1 |
| Almirante, B; Pemán, J | 1 |
| Ruiz Camps, I; Vázquez López, L | 1 |
| Chandrasekar, PH; Cutright, JL; Krishnan-Natesan, S; Manavathu, EK | 1 |
| Alastruey-Izquierdo, A; Goodwin, J; Gregson, L; Hope, WW; Howard, SJ; Livermore, J; Perlin, DS; Sharp, A; Warn, PA | 1 |
| Bocanegra, R; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Wiederhold, NP | 1 |
| Benjamin, DK; Clark, K; Dowell, JA; Driscoll, T; Gonzalez, CE; Kilaru, R; Roden, MM; Schranz, J; Seibel, NL; Walsh, TJ | 1 |
| Deziel, MR; Drusano, GL; Drusano, MF; Gumbo, T; Liu, W; Louie, A; Ma, L | 1 |
| Bennett, JE | 1 |
| Denning, DW; Morrissey, G; Morrissey, J; Oakley, KL; Verweij, PE | 1 |
| Bacher, J; Bell, A; Callender, DP; Groll, AH; McMillian, CL; Petraitiene, R; Petraitis, V; Schaufele, RL; Sein, T; Walsh, TJ | 1 |
| Bacher, J; Bell, A; Candelario, M; Groll, AH; Lyman, CA; McMillian, CL; Petraitiene, R; Petraitis, V; Sein, T; Walsh, TJ | 1 |
| Bacher, JS; Groll, AH; Lyman, CA; Mickiene, D; Petraitiene, R; Petraitis, V; Piscitelli, SC; Walsh, TJ | 1 |
3 review(s) available for anidulafungin and Neutropenia
| Article | Year |
|---|---|
[Current treatment of candidemia. Role of anidulafungin].
Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Candidiasis; Clinical Trials as Topic; Disease Susceptibility; Double-Blind Method; Drug Resistance, Fungal; Echinocandins; Fluconazole; Fungemia; Gastrointestinal Diseases; Global Health; Humans; Middle Aged; Multicenter Studies as Topic; Neutropenia; Risk Factors; Species Specificity | 2008 |
[Potential of anidulafungin in hematological patients].
Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Azoles; Candidiasis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Echinocandins; Fungemia; Hematologic Diseases; Hematologic Neoplasms; Humans; Inactivation, Metabolic; Kidney Diseases; Liver Diseases; Mice; Neutropenia; Risk Factors | 2008 |
Echinocandins for candidemia in adults without neutropenia.
Topics: Anidulafungin; Antifungal Agents; beta-Glucans; Candida; Candidiasis; Caspofungin; Cross Infection; Echinocandins; Fungemia; Humans; Infusions, Intravenous; Lipopeptides; Lipoproteins; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Neutropenia; Peptides, Cyclic; Practice Guidelines as Topic | 2006 |
12 other study(ies) available for anidulafungin and Neutropenia
| Article | Year |
|---|---|
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
Topics: Anidulafungin; Animals; Antifungal Agents; Area Under Curve; Candida; Candidiasis; Disease Models, Animal; Echinocandins; Female; Humans; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Treatment Outcome | 2008 |
Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy.
Topics: Aged; Antifungal Agents; Echinocandins; Fatal Outcome; Geotrichosis; Geotrichum; Humans; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Neutropenia | 2009 |
Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.
Topics: Anidulafungin; Animals; Antifungal Agents; Area Under Curve; Aspergillus fumigatus; Disease Models, Animal; Drug Therapy, Combination; Echinocandins; Female; Humans; Invasive Pulmonary Aspergillosis; Microbial Sensitivity Tests; Neutropenia; Pyrimidines; Rats; Treatment Outcome; Triazoles; Voriconazole | 2009 |
Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model.
Topics: Anidulafungin; Animals; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Disease Models, Animal; Echinocandins; Female; Fluconazole; Humans; Immunocompromised Host; Kidney; Lipopeptides; Mice; Mice, Inbred ICR; Neutropenia; Spleen; Treatment Outcome | 2010 |
Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Topics: Anidulafungin; Animals; Antifungal Agents; Candida glabrata; Candidiasis; Caspofungin; Dose-Response Relationship, Drug; Echinocandins; Humans; Lipopeptides; Male; Micafungin; Mice; Microbial Sensitivity Tests; Neutropenia | 2011 |
Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.
Topics: Anidulafungin; Animals; Antifungal Agents; beta-Glucans; Blood; Blood Chemical Analysis; Candida albicans; Candidiasis, Invasive; Colony Count, Microbial; Disease Models, Animal; Echinocandins; Fluconazole; Mice; Mice, Inbred ICR; Neutropenia; Proteoglycans; Survival Analysis; Treatment Outcome | 2012 |
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
Topics: Adolescent; Anidulafungin; Antifungal Agents; Child; Child, Preschool; Echinocandins; Female; Humans; Male; Mycoses; Neutropenia; Peptides, Cyclic | 2006 |
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Topics: Algorithms; Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Area Under Curve; Candida glabrata; Candidiasis; Colony Count, Microbial; Dose-Response Relationship, Drug; Echinocandins; Female; Fluconazole; Mice; Microbial Sensitivity Tests; Neutropenia; Peptides, Cyclic | 2006 |
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Colony Count, Microbial; Cyclophosphamide; Drug Resistance, Microbial; Echinocandins; Immunocompromised Host; Immunosuppressive Agents; Male; Mice; Microbial Sensitivity Tests; Neutropenia; Peptides, Cyclic | 1998 |
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Dose-Response Relationship, Drug; Echinocandins; Female; Lung Diseases, Fungal; Neutropenia; Peptides, Cyclic; Rabbits | 1998 |
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
Topics: Amphotericin B; Analysis of Variance; Anidulafungin; Animals; Antifungal Agents; Candida albicans; Candidiasis; Creatinine; Dose-Response Relationship, Drug; Echinocandins; Female; Fluconazole; Metabolic Clearance Rate; Microbial Sensitivity Tests; Neutropenia; Peptides, Cyclic; Potassium; Rabbits | 1999 |
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
Topics: Anidulafungin; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Disease Models, Animal; Echinocandins; Female; Lung Diseases, Fungal; Neutropenia; Opportunistic Infections; Peptides, Cyclic; Rabbits; Tissue Distribution | 2001 |